WO2007132179A3 - Therapeutics comprising pyridinium derivatives - Google Patents

Therapeutics comprising pyridinium derivatives Download PDF

Info

Publication number
WO2007132179A3
WO2007132179A3 PCT/GB2007/001684 GB2007001684W WO2007132179A3 WO 2007132179 A3 WO2007132179 A3 WO 2007132179A3 GB 2007001684 W GB2007001684 W GB 2007001684W WO 2007132179 A3 WO2007132179 A3 WO 2007132179A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
pancreatic
modulating
brain
heart
Prior art date
Application number
PCT/GB2007/001684
Other languages
French (fr)
Other versions
WO2007132179A2 (en
Inventor
Barry Victor Lloyd Potter
James Dowden
Antony Galione
Andreas H Guse
Alexander Fluegel
Original Assignee
Univ Bath
Barry Victor Lloyd Potter
James Dowden
Antony Galione
Andreas H Guse
Alexander Fluegel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/422,010 external-priority patent/US20070105810A1/en
Application filed by Univ Bath, Barry Victor Lloyd Potter, James Dowden, Antony Galione, Andreas H Guse, Alexander Fluegel filed Critical Univ Bath
Publication of WO2007132179A2 publication Critical patent/WO2007132179A2/en
Publication of WO2007132179A3 publication Critical patent/WO2007132179A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/452—Piperidinium derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)

Abstract

The present invention relates to the use of a compound of formula (1) wherein: R1 comprises a carbonyl group and R2 is a hydrocarbyl group; optionally wherein said ring is further substituted; or a pharmaceutically acceptable salt thereof; in the manufacture of a medicament for use in one or more of: modulating the release of intracellular calcium from a store controlled by nicotinic acid adenine dinucleotide phosphate; modulating calcium spikes in mammalian cells; treating diseases in one or more of brain, heart, pancreatic cells (e.g. pancreatic acinar and pancreatic beta cells), immune cells, T-cells, haemopoietic cells including phagocytes; treating diseases in one or more of brain, heart, pancreatic cells (e.g. pancreatic acinar and pancreatic beta cells), immune cells, T-cells, haemopoietic cells including phagocytes by modulating the release of intracellular calcium from a store controlled by nicotinic acid adenine dinucleotide phosphate; treating diseases in one or more of brain, heart, and T-cells by modulating calcium spikes in mammalian cells.
PCT/GB2007/001684 2006-05-15 2007-05-09 Therapeutics comprising pyridinium derivatives WO2007132179A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US80061906P 2006-05-15 2006-05-15
US60/800,619 2006-05-15
US11/422,010 US20070105810A1 (en) 2003-12-05 2006-06-02 Therapeutics
US11/422,010 2006-06-02

Publications (2)

Publication Number Publication Date
WO2007132179A2 WO2007132179A2 (en) 2007-11-22
WO2007132179A3 true WO2007132179A3 (en) 2008-03-27

Family

ID=38624352

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2007/001684 WO2007132179A2 (en) 2006-05-15 2007-05-09 Therapeutics comprising pyridinium derivatives

Country Status (1)

Country Link
WO (1) WO2007132179A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102491944A (en) * 2011-12-13 2012-06-13 东阳市威达环保助剂有限公司 Method for preparing brominated 1-benzyl-3-carboxypyridine and preparation method thereof
WO2016024246A1 (en) * 2014-08-14 2016-02-18 Universita' Degli Studi Di Roma 'la Sapienza' A therapeutic use of naadp and/or tcp2 antagonists
WO2023230205A1 (en) 2022-05-25 2023-11-30 Ikena Oncology, Inc. Mek inhibitors and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998044925A1 (en) * 1997-04-04 1998-10-15 Smithkline Beecham Corporation Calcilytic compounds
WO2001025209A1 (en) * 1999-10-06 2001-04-12 Torrent Pharmaceuticals Ltd Pyridinium derivatives for the treatment of diabetic and aging-related vascular complications
WO2002011736A1 (en) * 2000-08-04 2002-02-14 University Of Bath Naadp analogues for modulating t-cell activity
WO2005054198A2 (en) * 2003-12-05 2005-06-16 University Of Bath Therapeutics use of pyridinium compounds to modulate naadp activity

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998044925A1 (en) * 1997-04-04 1998-10-15 Smithkline Beecham Corporation Calcilytic compounds
WO2001025209A1 (en) * 1999-10-06 2001-04-12 Torrent Pharmaceuticals Ltd Pyridinium derivatives for the treatment of diabetic and aging-related vascular complications
WO2002011736A1 (en) * 2000-08-04 2002-02-14 University Of Bath Naadp analogues for modulating t-cell activity
WO2005054198A2 (en) * 2003-12-05 2005-06-16 University Of Bath Therapeutics use of pyridinium compounds to modulate naadp activity

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DOWDEN JAMES ET AL: "Cell-permeant small-molecule modulators of NAADP-mediated Ca2+ release", CHEMISTRY & BIOLOGY (CAMBRIDGE), vol. 13, no. 6, June 2006 (2006-06-01), pages 659 - 665, XP002465203, ISSN: 1074-5521 *
DUNTZE W ET AL: "Alkylation of nicotinamide and nicotinic acid by tetramin- (1 aziridino-2-hydroxybut-3-ene) and other carcinostatic ethylenimine derivatives", ZEITSCHRIFT FUER KREBSFORSCHUNG, SPRINGER VERLAG, BERLIN, DE, 1962, pages 503 - 518, XP008087245, ISSN: 0301-1585 *
ESCH VAN J H ET AL: "REDUCTION OF NICOTINAMIDES, FLAVINS, AND MANGANESE PORPHYRINS BY FORMATS, CATALYZED BY MEMBRANE-BOUND RHODIUM COMPLEXES", JOURNAL OF ORGANIC CHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, US, vol. 60, no. 6, 1995, pages 1599 - 1610, XP008044842, ISSN: 0022-3263 *
FARAG H H ET AL: "SYNTHESIS AND PRELIMINARY ALKYLATING ACTIVITIES OF CERTAIN NEW 1,4-DIHYDROPYRIDINES, PYRIDINIUM SALTS AND 2,7-DIAZABICYCLO [4.1.0] HEPT-3-ENES", BULLETIN OF PHARMACEUTICAL SCIENCES, ASSIUT UNIVERSITY PRESS, ASSIUT, EG, vol. 16, no. 2, 1993, pages 141 - 150, XP008044846, ISSN: 1110-0052 *
KHALID M KHAN ET AL: "SYNTHESES OF SELECTED QUATERNARY PHENACYLBROMOPYRIDINIUM COMPOUNDS AND THEIR BIOLOGICAL EVOLUTION", ZEITSCHRIFT FUR NATURFORSCHUNG, TEIL B: ANORGANISCHE CHEMIE, ORGANISCHE CHEMIE, VERLAG DER ZEITSCHRIFT FUR NATURFORSCHUNG. TUBINGEN, DE, vol. 54 (9), 1999, pages 1210 - 1218, XP008087298, ISSN: 0932-0776 *
M.P. SCHUBERT: "The interaction of iodoacetic acid and tertiary amines", J. BIOL. CHEM., 1936, pages 437 - 445, XP002465202 *
ZHENG, FANG ET AL: "QSAR modeling of mono- and bis-quaternary ammonium salts that act as antagonists at neuronal nicotinic acetylcholine receptors mediating dopamine release", BIOORGANIC & MEDICINAL CHEMISTRY , 14(9), 3017-3037 CODEN: BMECEP; ISSN: 0968-0896, 2006, XP002465201 *

Also Published As

Publication number Publication date
WO2007132179A2 (en) 2007-11-22

Similar Documents

Publication Publication Date Title
CR20230230A (en) Process for making a pd-1/pd-l1 inhibitor and salts and crystalline forms thereof
KR102642823B1 (en) Compositions and methods for controlling hair growth
EP1828167B1 (en) Acrylamide derivatives as antibiotic agents
CN105051041B (en) Heterocycle glutamine enzyme inhibitor
CN106795099B (en) For treating the prodrug and composition of hypertension and cardiovascular disease
MX347544B (en) Polycyclic lpa1 antagonist and uses thereof.
AU2009258496A8 (en) Sulfur-containing heterocyclic derivative having beta-secretase-inhibiting activity
NZ596200A (en) Intravenous formulation with water-soluble cocrystals of acetylsalicylic acid and theanine
NZ596392A (en) Thieno [2, 3-b] pyridine derivatives as viral replication inhibitors
TW200637839A (en) 1-thio-d-glucitol derivatives
TW200716648A (en) Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
MX2007007458A (en) Quinazoline derivatives for inhibiting cancer cell growth and method for the preparation thereof.
UA116992C2 (en) Treatment of immune-related and inflammatory diseases
AU2011327113A8 (en) Crystalline 6,7-unsaturated-7-carbamoyl morphinane derivative, and method for producing same
GB2454615A (en) Antidiabetic azabicyclo (3.1.0) hexan compounds
MX2009010731A (en) 1-(1-benzylpiperidin-4-yl)benzimidaz0le -5-carboxylic acid derivatives for the treatment of diabetes mellitus.
WO2009018065A3 (en) Novel glucokinase activators and methods of using same
SG11201407575PA (en) 5-amino[1,4]thiazines as bace 1 inhibitors
JP2017529315A (en) Use of isoquinoline alkaloid derivatives for the manufacture of a medicament for activating AMP-dependent protein kinase
WO2007132179A3 (en) Therapeutics comprising pyridinium derivatives
IL153561A0 (en) 4-alkoxy cyclohexane-1-amino carboxylic acid esters and method for the production thereof
BR112012016128A8 (en) THERAPEUTIC AGENT (Y-39983) FOR CORNEAL ENDOTHELIAL DYSFUNCTION
MX2020013847A (en) Crystal form of compound for inhibiting the activity of cdk4/6 and use thereof.
WO2005054198A3 (en) Therapeutics use of pyridinium compounds to modulate naadp activity
TW201136940A (en) Carboxylic acid derivatives comprising a 2,5,7-substituted oxazolopyrimidine ring

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07732712

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07732712

Country of ref document: EP

Kind code of ref document: A2